Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-07-14
1999-11-09
Moezie, F. T.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530324, A61K 3827
Patent
active
059814853
ABSTRACT:
A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
REFERENCES:
patent: 3928137 (1975-12-01), Monte et al.
patent: 4100271 (1978-07-01), Krezanoski
patent: 4188373 (1980-02-01), Krezanoski
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4357310 (1982-11-01), Chan et al.
patent: 4474752 (1984-10-01), Haslam et al.
patent: 4474753 (1984-10-01), Haslam et al.
patent: 4623717 (1986-11-01), Fernandes et al.
patent: 4637834 (1987-01-01), Thurow
patent: 4783441 (1988-11-01), Thurow
patent: 4812557 (1989-03-01), Yasushi et al.
patent: 4816568 (1989-03-01), Hamilton et al.
patent: 4857505 (1989-08-01), Arendt
patent: 4857506 (1989-08-01), Tyle
patent: 4917685 (1990-04-01), Viswanathan et al.
patent: 4992419 (1991-02-01), Woog et al.
patent: 5008244 (1991-04-01), Miller et al.
patent: 5096885 (1992-03-01), Pearlman et al.
patent: 5126324 (1992-06-01), Clark et al.
patent: 5182258 (1993-01-01), Chiou
patent: 5317012 (1994-05-01), Kudsk
patent: 5374620 (1994-12-01), Clark et al.
patent: 5567677 (1996-10-01), Castensson et al.
patent: 5597802 (1997-01-01), Clark et al.
patent: 5763394 (1998-06-01), O'Connor et al.
Research Disclosure RD 370013, "Stabilised protein formulations, particularly, for somatotropin implants-contain stabilising polyol, buffer, wetting agent and alkali metal halide" (Feb. 10, 1995).
Brange Jens et al., "Galenics of Insulin," Springer-Verlag, Berlin, Heidelberg (1987) pp. 67-68.
Clarke et al., "Method of formulating IGF-1 with growth hormone," Journal of Biotechnology Advances, vol. 15, No. 3-4, p785.
Chawla et al., "Aggregation of Insulin, containing surfactants, in contact with different materials," Diabetes (1985) 34:420-424.
Dellacha et al., "Physicochemical behaviour and biological activity of bovine growth hormone in acidic solution,"Biochemical Et Biophysica ACTA (1968) 168:95-105.
Lougheed et al., "Physical Stability of Insulin Formulations," 32:424-432 (1983).
Manning et al., "Stability of Protein Pharmaceuticals," Pharmaceutical Research, vol. 6, No. 11, pp. 903-917 (1989).
Thurow et al., "Stabilisation of dissolved proteins against denaturation at hydrophobic interfaces," Diabetologia, 27:212-218 (1984).
Yoshihiro, "Making preparations: Formulations," Journal Iyakuhin Kenkyu, vol. 20, No. 3, pp. 584-586 (1989).
Physician's Desk Reference, Orawell, NJ:Medical Economics Co. pp. 1049-1050 (1992).
Physician's Desk Reference, Orawell, NJ:Medical Economics Co. pp. 1266-1267 (1992).
The Merck Index, Rahway, NJ:Merck & Co. Inc. p. 983, entry No. 7342 (1976).
The Merck Index, Rahway, NJ:Merck & Co. Inc. p. 1203, entry No. 7537 (1989).
Physician's Desk Reference, Orawell, NJ:Medical Economics Co. pp. 1193-1194 (1988).
Becker et al., "Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormone" Biotechnology and Applied Biochemistry 9:478-487 (1987).
Pearlman et al. Current Communications in Molecular Biology, D. Marshak, D. Liu pp. 23-30 (1989).
Skottner et al., "Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I" Endocrinology 124(5):2519-2526 (1989).
O'Connor Barbara H.
Oeswein James Q.
Genentech Inc.
Moezie F. T.
LandOfFree
Human growth hormone aqueous formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human growth hormone aqueous formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human growth hormone aqueous formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1455990